Edwards Lifesciences Reports Second Quarter Results
Thursday, July 23, 2026 1 min read
Key Takeaway: Edwards Lifesciences reported a strong financial performance for Q2 2026, with sales rising 13.6% to $1.74 billion. TAVR sales also showed significant growth, increasing by 11.3%. The company's adjusted EPS was reported at $0.78, reflecting robust earnings. Recent clinical data further supports their leading position in the market.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas
Frequently Asked Questions
What were Edwards Lifesciences' Q2 sales figures?
Edwards Lifesciences reported Q2 sales of $1.74 billion, a 13.6% increase.
How much did TAVR sales grow in Q2?
TAVR sales grew by 11.3% to reach $1.26 billion in Q2.
What was the adjusted EPS for Q2 2026?
The adjusted EPS for Q2 2026 was reported at $0.78.
What drove the TMTT sales in Q2?
TMTT sales of $195.9 million were driven by a portfolio of repair and replacement therapies.